Back to Stocks

ALKS

Alkermes plc.
7 filings tracked
healthcarebiotechnologyMID ($2B-10B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Alkermes has effectively pivoted its strategic trajectory with the $2.3 billion acquisition of Avadel Pharmaceuticals, integrating LUMRYZ into its portfolio.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the top-line growth, Alkermes' operational health is under pressure as the company swings to a $48 million operating loss.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every ALKS filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company in the midst of a high-stakes transformation. By aggressively leveraging its balance sheet to acquire Avadel, Alkermes has traded short-term profitability and cash reserves for long-term strategic positioning in the sleep medicine market. The immediate revenue jump is promising, but the transition has introduced substantial debt service obligations and accounting complexities that mask the true operational margin. Investors are now faced with a classic biotech trade-off: the certainty of increased leverage and short-term losses versus the potential for blockbuster returns from LUMRYZ and the Alixorexton pipeline. The success of this transition will likely depend on the speed of LUMRYZ's commercial ramp-up and the outcome of the Phase 3 Brilliance Studies. Until these catalysts materialize, the stock will likely remain sensitive to interest rate fluctuations and the resolution of its ongoing intellectual property litigation.

Selected Quarter

Core Takeaway

Alkermes has shifted from a niche psychiatric player to a diversified neuroscience company, but at the cost of $1.5B in new debt and immediate operating losses.

Investor Lens

The trade-off between immediate balance sheet deterioration and the long-term potential of a dominant position in the narcolepsy market.

Watch Next

Phase 3 Brilliance Studies data for Alixorexton and the commercial run-rate of LUMRYZ in subsequent quarters.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.09Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 5

Acquired Avadel Pharmaceuticals for $2.3B, adding LUMRYZ and a narcolepsy commercial organization.

acquisition
90%
bearishMay 5

Increased long-term debt by $1.525 billion to fund the Avadel acquisition.

capital raise
70%
bearishMay 5

Operating income swung to a loss due to acquisition costs and inventory step-up amortization.

margin compression
60%
bullishMay 5

Total revenues grew 28% YoY, driven by strong performance in LYBALVI and ARISTADA.

earnings beat
75%
bullishMay 5

Acquired Avadel Pharmaceuticals for $2.3B, adding LUMRYZ and a narcolepsy commercial organization.

acquisition
90%
bearishMay 5

Increased long-term debt by $1.525 billion to fund the Avadel acquisition.

capital raise
70%
bearishMay 5

Operating income swung to a loss due to acquisition costs and inventory step-up amortization.

margin compression
60%
bullishMay 5

Total revenues grew 28% YoY, driven by strong performance in LYBALVI and ARISTADA.

earnings beat
75%
bullishMay 5

Acquired Avadel Pharmaceuticals for $2.3B, adding LUMRYZ and a narcolepsy commercial organization.

acquisition
90%
bearishMay 5

Increased long-term debt by $1.525 billion to fund the Avadel acquisition.

capital raise
70%
bearishMay 5

Operating income swung to a loss due to acquisition costs and inventory step-up amortization.

margin compression
60%
bullishMay 5

Total revenues grew 28% YoY, driven by strong performance in LYBALVI and ARISTADA.

earnings beat
75%
bullishMay 5

Acquired Avadel Pharmaceuticals for $2.3B, adding LUMRYZ and a narcolepsy commercial organization.

acquisition
90%
bearishMay 5

Increased long-term debt by $1.525 billion to fund the Avadel acquisition.

capital raise
70%
bearishMay 5

Operating income swung to a loss due to acquisition costs and inventory step-up amortization.

margin compression
60%
bullishMay 5

Total revenues grew 28% YoY, driven by strong performance in LYBALVI and ARISTADA.

earnings beat
75%
bullishMay 5

Acquired Avadel Pharmaceuticals for $2.3B, adding LUMRYZ and a narcolepsy commercial organization.

acquisition
90%
bearishMay 5

Increased long-term debt by $1.525 billion to fund the Avadel acquisition.

capital raise
70%
bearishMay 5

Operating income swung to a loss due to acquisition costs and inventory step-up amortization.

margin compression
60%
bullishMay 5

Total revenues grew 28% YoY, driven by strong performance in LYBALVI and ARISTADA.

earnings beat
75%
bullishMay 5

Acquired Avadel Pharmaceuticals for $2.3B, adding LUMRYZ and a narcolepsy commercial organization.

acquisition
90%
bearishMay 5

Increased long-term debt by $1.525 billion to fund the Avadel acquisition.

capital raise
70%
bearishMay 5

Operating income swung to a loss due to acquisition costs and inventory step-up amortization.

margin compression
60%
bullishMay 5

Total revenues grew 28% YoY, driven by strong performance in LYBALVI and ARISTADA.

earnings beat
75%
bullishMay 5

Acquired Avadel Pharmaceuticals for $2.3B, adding LUMRYZ and a narcolepsy commercial organization.

acquisition
90%
bearishMay 5

Increased long-term debt by $1.525 billion to fund the Avadel acquisition.

capital raise
70%
bearishMay 5

Operating income swung to a loss due to acquisition costs and inventory step-up amortization.

margin compression
60%
bullishMay 5

Total revenues grew 28% YoY, driven by strong performance in LYBALVI and ARISTADA.

earnings beat
75%

Filing History

10-QMay 5, 2026
Expand Sequence

The Q1 2026 filing reveals a company in the midst of a high-stakes transformation. By aggressively leveraging its balance sheet to acquire Avadel, Alkermes has traded short-term profitability and cash reserves for long-term strategic positioning in the sleep medicine market. The immediate revenue jump is promising, but the transition has introduced substantial debt service obligations and accounting complexities that mask the true operational margin. Investors are now faced with a classic biotech trade-off: the certainty of increased leverage and short-term losses versus the potential for blockbuster returns from LUMRYZ and the Alixorexton pipeline. The success of this transition will likely depend on the speed of LUMRYZ's commercial ramp-up and the outcome of the Phase 3 Brilliance Studies. Until these catalysts materialize, the stock will likely remain sensitive to interest rate fluctuations and the resolution of its ongoing intellectual property litigation.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.